Feb 28 2008
Günther Hofmann, Chief Operating Officer of PHOTO DYNAMIC THERAPY LLC (PDT®), a Vienna, Austria based company providing their propriate PHOTONIC TUMOR THERAPY SYSTEM to the healthcare market as a clinical all-in service, is currently on the road show in the United States from the east to the west. He will give his next presentation in LAS VEGAS at the In3 WEST conference at THE VENETIAN on Thursday, February 28, 2008, 11:10 - 11:20 AM. The focus is to identify strategic partners for the worldwide roll out of PHOTONIC TUMOR THERAPY SYSTEM in developed countries.
The use of the company’s effective and safe PHOTONIC TUMOR THERAPY SYSTEM offers the opportunity to change an aggressive tumor disease into a chronic, in a number of cases not life limiting sickness with high quality of life. The repeated, easy, simple and risk less to perform interventions, often on outpatient base, with a low side effect profile in a highly acceptable ratio of outcome and disease.
The commercial advantage of the PHOTONIC TUMOR THERAPY SYSTEM is the cost-per-treatment for the all-in service provided by specifically trained clinical advisors. Additionally the service covers proprietary SOPs, technical hands-on OR support, the use of medical devices as well as the administration support for marketing and reimbursement. The low cost in line with the reimbursement optimizes budgeting and cost control. The company gains advantage from short decision cycles and this accelerates the market penetration.
The market of PHOTONIC THERAPY is substantial and continues to grow due to an aging population, circumstances of life, better diagnostics and inadequacy of current treatment modalities: Ferlay J, et al. reported 2006 about the EC 25 an increase of 51,8%, i.e. 580.000 deaths between 2000 and 2006. The new cases rose 300.000 to 3,2 million in 2004 to 2006. Jemal A, et al., reported 2007 for the US the same trends, depending on the population with lower absolute figures.
PDT® a privately held company, Vienna, Austria based, markets their proprietary PHOTONIC TUMOR THERAPY SYSTEM for non-invasive, curative and palliative treatment of tumors and precursors.
Laser light adapted to patients’ biomedical needs generates oxygen radicals causing tumor cell death and prevention to healthy cells.
PDT® provides a unique all-in service on cost-per-treatment. With proprietary SOPs, procedural advice, technical hands-on, medical devices and reimbursement support.
Now available for bile duct, bladder, cardia, cervix, colon, esophagus, lung, pancreas and rectum.
Patents granted in all developed markets.
The safe and effective tumor treatment shall encourage companies to enter strategic partnerships or to in-license IP.